Cell therapies: the race without an ethical compass

We have been following, in recent weeks, the question of human embryoids and genetically modified embryos, two new ethical boundaries. The debate now extends to an immediate clinical issue: that of cellular therapies and the origin of the cells they use.

Context

Cellular therapies are experiencing an unprecedented acceleration: degenerative, cardiac, oncological diseases. Three paths coexist, morally incommensurable. Cells of embryonic origin, obtained by the destruction of a human embryo. Fetal cells, derived from tissues collected after abortion. Induced pluripotent stem cells (iPS), reprogrammed from adult cells, without destruction. Since the work of Shinya Yamanaka (Nobel 2012), the third path has proven itself and opens a complete ethical alternative.

Facts

Gènéthique reports, on July 15, 2026, the rapid progress of the three paths. The announced clinical protocols often do not publicly distinguish their cellular origin; some promoters indistinctly present embryonic therapies and iPS under a generic term of "regenerative cellular therapies". The observatory notes several European trials in phase II using historical embryonic lines (WA-09, H-9) without explicit mention in patient consents. The informational void is not neutral: it makes the patient's moral choice impossible.

Doctrinal Analysis

The Church's position is clear and constant. The Catechism teaches that "the embryo must be treated as a person from the moment of conception" and that one must "defend its integrity, care for it, and heal it as far as possible like any other human being" (CCC n° 2274). The Congregation for the Doctrine of the Faith, in Dignitas personae (2008), strictly distinguishes embryonic stem cells (obtained at the cost of the destruction of the embryo, morally unacceptable) from adult stem cells and iPS, morally licit. The same document specifies that the therapeutic use of biological material of illicit origin calls for a discernment based on the classic criteria of material cooperation. Evangelium vitae recalled: "no circumstance, no purpose, no law in the world will ever be able to make licit an act that is intrinsically illicit, because it is contrary to the Law of God" (EV n° 62).

Stakes for the Church and the Faithful

Three questions arise. The duty of traceability: the faithful patient must be able to know the cellular origin of the proposed treatment. The responsibility of Catholic doctors and pharmacists, who must, under the conscience clause, refuse any formal participation in embryonic therapy. The political urgency finally: to ask the European (EMA) and French (HAS, ANSM) authorities for a mandatory mention of the cellular origin in the therapeutic notices and consent protocols.

Critical Reading and Blind Spots

The success of iPS provides a concrete ethical alternative. The embryonic path can no longer claim a scientific necessity: it now falls under an ideological choice. But the pharmaceutical industry, having invested in embryonic lines, resists their obsolescence. The major blind spot: cells derived from aborted fetuses (HEK-293 in particular for the production of certain medicines and vaccines), still trivialized without debate.

To Reflect and Act

Pray for researchers who, like Jérôme Lejeune, refuse the logic of destruction. Ask your doctor about the origin of treatments. Support foundations and laboratories that, in Europe and the United States, exclusively develop iPS and adult cell lines. Science can, it must, respect the human person from the moment of conception.